-
DE
Friedreich ataxia is a rare, inherited neurological disorder causing progressive loss of coordination, balance, and muscle control.
Regular tips about health Regular tips about health Add as Preferred SourceFriedreich ataxia is a rare, inherited neurological disorder causing progressive loss of coordination, balance, and muscle control.
Friedreich ataxia is the most common hereditary ataxia worldwide. It is a progressive neurodegenerative disease that primarily affects the cerebellum, spinal cord, and peripheral nerves. The condition was first described in 1863 by German physician Nikolaus Friedreich. Approximately 1 in 50,000 people in Europe is affected, and symptoms typically begin in childhood or adolescence.
Friedreich ataxia is caused by mutations in the FXN gene on chromosome 9, which encodes the protein frataxin. In the vast majority of cases, the mutation consists of an abnormal expansion of a GAA trinucleotide repeat sequence within this gene. This expansion silences the gene, resulting in critically reduced frataxin production.
Frataxin is essential for mitochondrial iron metabolism. Without sufficient frataxin, iron accumulates inside the mitochondria, triggering oxidative stress and ultimately causing cell death in nerve cells and cardiomyocytes (heart muscle cells).
The disease follows an autosomal recessive inheritance pattern, meaning a child must inherit a defective copy of the FXN gene from both parents in order to develop the condition.
The first symptoms typically appear between the ages of 5 and 15, though late-onset cases do occur. Disease progression is continuous, though the rate varies between individuals.
Diagnosis is based on a combination of clinical evaluation, neurological testing, and molecular genetic analysis.
There is currently no cure for Friedreich ataxia. However, since 2023, the first approved disease-modifying treatment – omaveloxolone (brand name: Skyclarys) – has become available in the United States and subsequently in Europe. This drug activates the Nrf2 pathway to reduce mitochondrial oxidative stress and has been shown to slow neurological decline.
Active research is underway on gene therapy approaches aimed at restoring FXN gene expression, as well as epigenetic strategies to increase frataxin production. Multiple clinical trials are ongoing worldwide, and the therapeutic outlook continues to improve.
Most patients require a wheelchair within 10–15 years of symptom onset. Life expectancy is primarily limited by cardiac complications. Many patients live into middle adulthood, and some into later life. A multidisciplinary care team and early intervention significantly improve quality of life and functional independence.
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Average rating of 4.97 out of 5 stars
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
Average rating of 4.85 out of 5 stars
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
Average rating of 4.86 out of 5 stars
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
Average rating of 4.94 out of 5 stars
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.